Immunotherapy Study for Surgically Resected Pancreatic Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess overall survival after treatment with a regimen of
adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without
HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical
resection.